Health News Releases

  • Today October 18
HistoSonics Announces Oversubscribed $250 Million Growth Financing
October 17, 14:50
HistoSonics Announces Oversubscribed $250 Million Growth Financing
HistoSonics, Inc., the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the closing of an oversubscribed $250 million financing led by its new owners
Credits to Roquette
October 17, 14:15
New Roquette Pharmaceutical Innovation Center to Strengthen Latin America as Collaborative Hub
Roquette, a global leader in plant-based ingredients and pharmaceutical excipients for health, nutrition and bio industrial markets, today, celebrates the grand opening of its dedicated Health & Pharm
October 16, 16:15
SS&C Technologies Completes Acquisition of Calastone
SS&C Technologies Holdings, Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ssctech.com%2F%3Futm_campaign%3DSSC2025-Enterprise-Press-Release-1025%26utm_medium%3Dpressreleas
October 15, 11:45
BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA
BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fbeonemedicines.com%2F&esheet=54337814&newsitemid=20251013125479&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5
October 14, 11:40
Parse Biosciences Invalidates Scale Biosciences (now 10x Genomics) Patent
Parse Biosciences (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.parsebiosciences.com%2F&esheet=54336442&newsitemid=20251009983648&lan=en-US&anchor=Parse+Biosciences&index=1&md
Pictured (L-R): Heidi co-founders Waleed Mussa, CFO; Dr. Thomas Kelly, CEO; and Yu Liu, CTO.
October 12, 13:00
Heidi Secures $65 Million USD in Series B Funding to Accelerate Building an AI Care Partner for Every Clinician
Heidi (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.heidihealth.com%2F&esheet=54334156&newsitemid=20251005012225&lan=en-US&anchor=Heidi&index=1&md5=660ced366440a0565290ef7747c
October 12, 11:00
Mundipharma announces patient enrolment completion in Phase III ReSPECT clinical trial for REZZAYO® (rezafungin)
Mundipharma today announced completion of patient enrolment for the ongoing, global Phase III ReSPECT trial evaluating REZZAYO® (rezafungin). The ReSPECT trial is a global, randomised, double-blind
A pharmacist advises a consumer on the purchase of Haleon’s Otrivin nasal mist.
October 12, 10:30
Haleon Selects Salesforce Agentforce Life Sciences Cloud for Customer Engagement to Improve Engagement with Pharmacies and Healthcare Professionals with AI
Haleon plc (LSE/NYSE:HLN), a leading global consumer company that specialises in everyday health and Salesforce (NYSE:CRM), the world’s #1 AI CRM, today announced that Haleon will leverage Salesforce
October 10, 17:20
Bimiralisib, Topical PI3K/mTOR Inhibitor Shows Up To 92% Clearance Rate And Superior Tolerability In Proof-Of-Concept Actinic Keratosis Study
Torqur AG, subsidiary of Swiss Rockets incubator and a clinical-stage company advancing targeted therapies in oncodermatology and oncology, announced the results of the full Phase 2 proof-of-concept s
October 10, 16:55
Tempus Joins Parse Biosciences’ Certified Service Provider Network
Parse Biosciences (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.parsebiosciences.com%2F&esheet=54333556&newsitemid=20251008146500&lan=en-US&anchor=Parse+Biosciences&index=1&md5
Masimo SET® Pulse Oximetry and RD SET® Sensors
October 10, 14:40
In Feasibility Study for Large, Prospective, Real-World Trial, Masimo SET® Performed Accurately on Critically Ill Adult ICU Patients of All Skin Tones
Masimo (https://www.masimo.com/) (NASDAQ: MASI) today announced the findings of an exploratory analysis for a unique feasibility study published in CHEST Critical Care in which Dr. Andrew Goodwin and
October 10, 11:10
TCG Crossover (“TCGX”) Announces Oversubscribed $1.3B TCGX Fund III
TCG Crossover (“TCGX”) today announced the successful closing of its third fund, TCGX Fund III, with $1.3 billion in capital commitments. Fund III attracted support from both current TCGX investors an
October 05, 11:55
Sobi Selects Kinaxis to Accelerate Access to Life-Changing Treatments
Kinaxis® (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.kinaxis.com%2Fen&esheet=54333058&newsitemid=20251002088321&lan=en-US&anchor=Kinaxis%26%23174%3B&index=1&md5=bc238f272987
October 05, 11:40
Neuraptive Therapeutics, Inc. Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating the Safety and Efficacy of NTX-001 Compared to Standard of Care in the Treatment of Upper Extremity Transected Nerves Requiring Surgical Repair
Neuraptive Therapeutics, Inc., a biotechnology company focused on developing novel therapies to improve outcomes in peripheral nerve injuries (PNI), today announced the first patient has been enrolled
WHOOP Launches Clinician-Reviewed Advanced Labs, Unlocking a Comprehensive View of Human Health
October 02, 14:50
WHOOP Launches Clinician-Reviewed Advanced Labs, Unlocking a Comprehensive View of Human Health
WHOOP (https://www.whoop.com/kr/en/), the human performance company, today announced the launch of WHOOP Advanced Labs (https://www.whoop.com/kr/en/advanced-labs/), a groundbreaking new feature that c
October 02, 14:50
Dentalis Earns 5 VOHC® Seals, Positioning for Global Expansion in Animal Health
Dentalis Animal Health Inc. is proud to announce a landmark achievement in veterinary dentistry: the company has been awarded five prestigious Veterinary Oral Health Council (VOHC®) Seals of Approval,
October 02, 11:10
Parse Biosciences Expands Global Access by Certifying Single Cell Discoveries as a Service Provider
Parse Biosciences (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.parsebiosciences.com%2F&esheet=54330033&newsitemid=20250930263922&lan=en-US&anchor=Parse+Biosciences&index=1&md5
October 01, 15:35
Microplastics in the Air: Global Study Uncovers Concerning Levels of Daily Exposure
The PlasticDustCloud project, a global study led by the Eurofins Environment Testing network, has revealed alarming microplastic pollution in air, with deposition rates of up to 1,300 microplastics pe
September 24, 16:10
AMWC Dubai: Galderma Demonstrates Injectable Aesthetics Leadership Through Updates on Its Scientific Innovations and Community Education
Galderma will present six posters with the latest updates from its science-backed aesthetic portfolio at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) in Dubai, United Arab Emirates, from
September 24, 15:30
Variational AI Enters Collaboration with Merck to Apply Generative AI to Drug Discovery
Variational AI, Inc., a generative AI drug discovery company, today announced a collaboration with Merck, known as MSD outside of the United States and Canada, to apply Variational AI’s Enki™ platform
September 24, 09:32
20,000 + Takeda Employees Voted to Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems in 94 Countries
Takeda (TOKYO:4502/NYSE: TAK) today committed JPY 4.6 billion (approx. USD 32.1 million) to four new Global Corporate Social Responsibility (CSR) partners as part of the company’s ongoing commitment t
September 18, 14:40
Rubedo Life Sciences Announces U.S. FDA Clearance of IND for Selective GPX4 Modulating Lead Drug Candidate RLS-1496 for Actinic Keratosis, Expands Clinical Advisory Board
Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced
Continuous Patient Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™
September 18, 14:25
New Study Finds That Using Masimo Technologies to Continuously Monitor General Floor Patients Reduces Costs
Masimo (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.masimo.com&esheet=54324636&newsitemid=20250917266545&lan=en-US&anchor=Masimo&index=1&md5=1c2d4fc2fd80ea476e53a7e74df69244)
September 18, 13:55
Merck to Present New Data Highlighting Durable Effects of MAVENCLAD® in Relapsing Multiple Sclerosis (RMS) at ECTRIMS 2025
Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of over 30 abstracts from its multiple sclerosis (MS) portfolio. Ne
September 17, 16:10
Galderma’s Groundbreaking Real-World Study Reveals the Biological Toll of Modern Living and Urban Environments on Sensitive Skin
Galderma today announced new data from a first-of-its-kind real-world clinical study conducted in China assessing the biological impact of different lifestyles and their associated environmental facto
Biocytogen Announces ADC Innovator Tubulis Has Signed Global Exclusive License Agreement for Single
September 17, 10:05
Biocytogen Announces ADC Innovator Tubulis Has Signed Global Exclusive License Agreement for Single Antibody
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technolo
September 17, 08:59
Takeda and VELA to Ship Medicines Across the Atlantic Using First-of-its-Kind Wind-Powered Trimaran
Takeda (TSE:4502/NYSE:TAK) and VELA Transport today announced their business partnership, with Takeda set to become the first biopharmaceutical company to transport its products between Europe and the
September 16, 17:35
FrieslandCampina Ingredients Expands R&D Capabilities with New State-of-the-Art Application Centre in Singapore
FrieslandCampina Ingredients, a global leader in proteins and prebiotics, has announced the opening of a new application centre in Singapore, representing a 30% increase of R&D space in the city-state
Group photo of representatives from MEDIPEAU Inc. and GNPharm at the conference venue
September 16, 14:00
MEDIPEAU Showcases its Film-Type Wound Dressing Cream at 51st Annual Fall Meeting of Korean Pediatric Association
MEDIPEAU Inc., a company specializing in therapeutic solutions for atopic dermatitis, introduced its groundbreaking “BARRICURE Aid Film MD” during the 51st Annual Fall Meeting of the Korean Pediatric
September 16, 09:45
Helmholtz Munich and Parse Biosciences GigaLab Generate World’s Largest Human Lung Tissue Perturbation Atlas
Helmholtz Munich and Parse Biosciences (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.parsebiosciences.com%2F&esheet=54323217&newsitemid=20250915189668&lan=en-US&anchor=Parse+Bi
RPTs: Pre-clinical Drug Discovery Pipeline
September 12, 16:20
Medicines Discovery Catapult and Crown Bioscience Form Strategic Global Alliance for Radiopharmaceutical Innovation
Medicines Discovery Catapult (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fmd.catapult.org.uk%2F&esheet=54321838&newsitemid=20250911458780&lan=en-US&anchor=Medicines+Discovery+Cat
September 12, 15:20
Ferring Japan announces PMDA Acceptance of NDA Filing for nadofaragene firadenovec
Ferring Pharmaceuticals Co., Ltd. announced that the PMDA has accepted the NDA for nadofaragene firadenovec for review, following submission on August 27th, 2025. This non-replicating gene therapy, ad
Aster Guardians Global Nursing Award worth USD 250,000 (Photo: AETOSWire)
September 12, 13:35
Nominations Open for Fifth Edition of Aster Guardians Global Nursing Award 2026 Worth USD 250,000
Aster DM Healthcare has announced the launch of the fifth edition of the Aster Guardians Global Nursing Award, one of the world’s most prominent recognition for nursing excellence worth USD 250,000.
September 12, 10:55
Promega and Watchmaker Genomics Announce Strategic Partnership to Advance Molecular Analysis with Next-Generation Reverse Transcriptase
Promega Corporation (https://www.promega.kr/?utm_source=businesswire.com&utm_medium=referral&utm_campaign=%28referral%29) has entered a strategic partnership with Watchmaker Genomics (https://www.watc
September 11, 15:50
EADV 2025: Galderma Reinforces Leadership in Dermatology With Latest Advances in Sensitive Skin and Itch
Galderma (SIX: GALD), the dermatology category leader, today announced it will unveil updates from its portfolio at the 34th European Academy of Dermatology and Venereology (EADV) congress, taking pla
September 10, 16:30
Galderma Launches Alastin® in China, Supporting the Skin’s Natural Regenerative Abilities in a Rapidly Expanding Market
Galderma (SIX: GALD) today announced the launch of four core Alastin® products in China, marking the premium medical skincare brand’s debut in one of the world’s fastest growing aesthetic skincare mar
September 10, 16:00
France Grants Reimbursed Compassionate Access (AAC) for Agenus’ BOT/BAL in Refractory MSS Metastatic Colorectal Cancer
Agenus Inc. (Nasdaq: AGEN), a leader in immuno‑oncology, today announced its investigational combination botensilimab plus balstilimab (BOT/BAL) is now available to eligible patients with refractory m
September 08, 17:39
Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&esheet=54319980&newsitemid=20250908503054&lan=en-US&ancho
September 07, 16:11
U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for VONVENDI® [von Willebrand factor (Rec
Amazfit is proud to celebrate Ruth Croft’s achievement at the 2025 UTMB, earning first place and com
September 07, 16:00
Amazfit Ambassador Ruth Croft Claims Victory at the 2025 UTMB
Amazfit (https://us.amazfit.com/), a leading global smart wearable brand by Zepp Health (NYSE: ZEPP), is proud to celebrate Ruth Croft’s achievement at the 2025 UTMB, earning first place and completin
Zepp Health (NYSE: ZEPP), the parent company of Amazfit, today announced it has acquired the core as
September 07, 15:50
Zepp Health Acquires Core Assets of Wild.AI to Expand Support for Female Athletes Across Life Stages
Zepp Health (NYSE: ZEPP), the parent company of Amazfit, today announced it has acquired the core assets and intellectual property of Wild.AI, a pioneering women’s wellness platform focused on optimiz
RIGAKU/JEOL-iCeMS Innovation Core
September 07, 12:20
Rigaku Joins Two Partners in Establishing RIGAKU/JEOL-iCeMS Innovation Core and Concluding a Cooperation Agreement
On September 4, 2025, Rigaku Corporation, a global solution partner in X-ray analytical systems and a Group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; President & CEO: Jun
Biocytogen Enters into Agreement with Merck to Advance Antibody-Conjugated Lipid-Based Delivery Solu
September 05, 17:15
Biocytogen Enters into Agreement with Merck to Advance Antibody-Conjugated Lipid-Based Delivery Solutions
Biocytogen Pharmaceuticals (https://biocytogen.com/) (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drug
September 05, 14:30
From AI-powered EHRs to Real-Time Data Sharing, InterSystems Asia Healthcare Summit 2025 Spotlights Indonesia as a Digital Health Beacon in Southeast Asia
InterSystems, a creative data technology provider managing more than one billion health records globally, recently held their Asia Healthcare Summit 2025, bringing together more than 200 regional and
Credit: IFF
September 05, 12:00
IFF’s Designed Enzymatic Biomaterials™ Platform Sees First Large-Scale Use in Home Care Applications
IFF (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.iff.com&esheet=54317958&newsitemid=20250904544995&lan=en-US&anchor=IFF&index=1&md5=6f4e9fc0d09b0ce3e1b691904d2aa7c2) (NYSE: I
September 04, 14:38
MRM Health Raises €55 Million Series B to Advance Best-in-Class Microbiome-Based Biotherapeutic Product Pipeline
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced the successful closing of a €55 millio
September 03, 16:40
Polpharma Biologics and MS Pharma Sign Licensing Agreements for Proposed Vedolizumab (PB016), Ocrelizumab (PB018) and Guselkumab (PB019) Biosimilars
Polpharma Biologics S.A. (“Polpharma Biologics”), specialized in the development and manufacturing of biosimilars, today announced that it has signed licensing agreements with MS Pharma, a leading bio
September 03, 09:53
Merck Appoints David Weinreich as New Global Head of R&D and Chief Medical Officer for Healthcare Business Sector
Merck, a leading science and technology company, today announced the appointment of David Weinreich, MD, MBA, as Global Head of R&D and Chief Medical Officer for its Healthcare business sector. Wei
IFF Tackles Top Challenges in Baking at IBIE 2025
September 03, 09:47
IFF Tackles Top Challenges in Baking at IBIE 2025
IFF (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.iff.com&esheet=54316321&newsitemid=20250902465856&lan=en-US&anchor=IFF&index=1&md5=e0f385d40a254be09c3e473ae8058dde) (NYSE: IF
August 31, 14:35
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
BeOne Medicines Ltd. (https://beonemedicines.com/) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) o
August 29, 11:30
Novotech Supports Groundbreaking Approval of Anlotinib Combination Therapy for Advanced Soft Tissue Sarcoma
Novotech, a globally recognized full-service clinical research organization (CRO), is proud to have partnered with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ Pharma) in achieving a signifi
(Credit: Reservas Votorantim) Images of Legado das Águas – Atlantic Forest Reserve in Brazil
August 28, 11:20
IFF and Reservas Votorantim Sign Bioprospecting Partnership in Brazil
IFF (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.iff.com%2F&esheet=54313323&newsitemid=20250827881934&lan=en-US&anchor=IFF&index=1&md5=aa3a4d050325a3165d01099ca70062f3) (NYSE
SBC Medical Appoints Dr. Ewen Chee as Lead Doctor for Asia Strategy to Accelerate Global Expansion
August 26, 13:40
SBC Medical Appoints Dr. Ewen Chee as Lead Doctor for Asia Strategy to Accelerate Global Expansion
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announ
August 26, 10:50
BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million
BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2F&esheet=54312218&newsitemid=20250825210828&lan=en-US&anchor=BeOne+Medicines+Ltd&index=1&md5
August 22, 09:35
European Commission Approves Tablet Formulation of BeOne Medicines’ BRUKINSA® for All Approved Indications
BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fbeonemedicines.com%2F&esheet=54311084&newsitemid=20250821182068&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5
August 13, 10:10
PL Developments Builds a Smarter, Healthier Supply Chain with Kinaxis
Kinaxis® (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.kinaxis.com%2Fen&esheet=54306533&newsitemid=20250812652131&lan=en-US&anchor=Kinaxis%26%23174%3B&index=1&md5=43390a81b573
August 08, 17:10
Polpharma Biologics and Fresenius Kabi Sign Licensing Agreement for Proposed Vedolizumab Biosimilar PB016
Polpharma Biologics S.A. (“Polpharma Biologics”) announces a global (except for Middle East & North Africa) licensing agreement with Fresenius Kabi for the commercialization of PB016, a proposed biosi
August 08, 15:00
BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates
BeOne Medicines Ltd. (https://beonemedicines.com/) (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the second quarter o
HistoSonics Non-Invasive Edison Histotripsy System Image credit: HistoSonics
August 08, 11:20
HistoSonics Announces $2.25B Acquisition by Consortium of Top-Tier Investors
HistoSonics (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.histosonics.com&esheet=54304409&newsitemid=20250807749442&lan=en-US&anchor=HistoSonics&index=1&md5=f0e9f5c34e97c8b8bfd
Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Study
August 05, 15:50
Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe
Concept Medical Inc. (https://www.conceptmedical.com/), a global pioneer in drug-delivery technologies, announced the enrollment of the first patient in the MAGICAL-SV (MAGIcTouch™ Sirolimus-Coated Ba
August 05, 15:00
Nucleus Network Acquires Hammersmith Medicines Research
Nucleus Network, a global leader in early phase clinical research, today announced the acquisition of Hammersmith Medicines Research (HMR), one of the United Kingdom’s most respected early phase clini
August 01, 13:40
BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom’s Macroglobulinemia
BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fbeonemedicines.com%2F&esheet=54299902&newsitemid=20250731014937&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5
July 30, 16:11
Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression
Takeda (TOKYO:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&esheet=54297300&newsitemid=20250727920112&lan=en-US&anc
XTRAIA XD-3300
July 30, 15:40
Rigaku Launches XTRAIA XD-3300 Mass Production for Semiconductor Market
Rigaku Corporation, a global solution partner in X-ray metrology systems and a Group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; hereinafter “Rigaku”), ha
Novotech Veeva Hero Award 2025 Recipient
July 30, 15:20
Novotech Awarded Veeva Hero Award at 2025 Veeva R&D and Quality Summit
Novotech, a globally recognized full-service clinical research organization (CRO), is proud to announce that we have received the highly regarded Veeva Hero award presented at the 2025 Veeva R&D and Q
BARRICURE booth at SPDU 2025, Imperial Hotel Kuching, Malaysia
July 29, 11:54
BARRICURE Officially Sponsors SPDU 2025 in Malaysia Collaborating with CHAYA AND LIGHT SDN. BHD. for Local Professional Promotion
BARRICURE, the dermatology-focused medical device brand of MEDIPEAU Inc, Ltd., participated as an official sponsor at the Sarawak Paediatric Dermatology Update 2025 (SPDU 2025), held on July 26, 2025,
July 29, 11:10
BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA® in Neoadjuvant/Adjuvant NSCLC Treatment
BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fbeonemedicines.com%2F&esheet=54297275&newsitemid=20250728331235&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md5
July 29, 10:55
Biocytogen Upgrades Preclinical Service Platform and Launches Revamped Global Website
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technolo
Software image
July 27, 10:33
Endoscopic AI: AI Medical Service Inc. Has Obtained Regulatory Approval from Thailand’s FDA for Its Gastric AI-based Endoscopic Diagnosis Support System
AI MEDICAL SERVICE INC. (hereinafter AIM), a medical start-up specializing in the development of diagnostic endoscopic AI, is excited to announce that it has received medical device approval from the
Amazfit Announces Ultra Runner Rod Farvard as New Brand Ambassador
July 25, 13:30
Amazfit Announces Ultra Runner Rod Farvard as New Brand Ambassador
Amazfit, a leading global smart wearables brand owned by Zepp Health (NYSE: ZEPP), announced ultra runner Rod Farvard as the newest athlete ambassador. Farvard’s approach to endurance racing, a combin
July 25, 11:30
LEO Pharma Announces FDA Approval of ANZUPGO® (delgocitinib) Cream in the U.S.
LEO Pharma, a global leader in medical dermatology, announced today that the U.S. Food and Drug Administration (FDA) has approved ANZUPGO® (delgocitinib) cream (20 mg/g) for the topical treatment of m
July 24, 14:52
Galderma Delivers Record First Half 2025 Net Sales of 2.448 Billion USD and 12.2% Year-on-Year Growth at Constant Currency, Raises Full-Year Top-Line Guidance
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the first half of 2025. · Record net sales of 2.448 billion USD, representing net
July 23, 14:30
Takeda Receives FDA 510(k) Clearance for HyHub™ and HyHub™ Duo Devices to Simplify HYQVIA® Administration
Takeda (TSE:4502/NYSE:TAK (https://www.takeda.com/investors/overview/)) today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for HyHub™ and HyHub™ Duo, devices
July 22, 14:05
SS&C Technologies to Acquire Calastone
SS&C Technologies Holdings, Inc. (https://www.ssctech.com/?utm_campaign=SSC2025-Enterprise-Press-Release-0725&utm_medium=pressrelease&utm_source=prnews&utm_content=SSNC-to-acquire-Calastone) (Nasdaq:
July 22, 14:00
Cloudbreak Pharma Inc. Announces Positive Phase 2 Results for CBT-004 in Patients with Vascularized Pinguecula
Cloudbreak Pharma Inc. a clinical-stage ophthalmology company developing innovative therapies for ocular surface diseases, today announced positive topline results from its Phase 2 clinical trial eval
25 per page50 per page75 per page100 per page